GlobeNewsWire
18 Nov 2026, 06:00 UTC · 14h ago
Zealand Pharma announces initiation of the Phase 2 ZYNERGY trial of petrelintide co-administered with enicepatide in people with obesity or overweight
Impact · against what's priced in
Zealand Pharma is advancing its obesity pipeline with the initiation of the Phase 2 ZYNERGY trial. The trial's design to test three dosing regimens of petrelintide and enicepatide provides a concrete path toward establishing the efficacy and safety profile needed for Phase 3 development.
- ZEAL+0.60
No priced-in read yet





